Summarized by Masters of Longevity from Longevity Technology.
Companies announced a partnership to pursue Japanese regulatory approval for PrecivityAD2.
Key Takeaways
- C2N and LSI Medience will seek Japanese approval for PrecivityAD2.
- They plan to commercialize the FDA-cleared Alzheimer’s blood test in Japan.
- Regulatory review is required and approval has not been established.
